natgillin/translations-raw huggingface dataset:
In the first stage of treatment, a sample of cartilage cells is taken from the patient’s joint and grown in a laboratory.
V prvi fazi zdravljenja se iz bolnikovega sklepa odvzame vzorec hrustančnih celic in razmnoži v laboratoriju.
In the first stage of treatment, a small part of healthy limbal tissue (12 mm2 in size) is taken from the patient in hospital and sent to the manufacturer on the same day.
V prvi fazi zdravljenja se bolniku v bolnišnici odvzame delček zdravega limbusnega tkiva (velikosti 12 mm2), ki se še isti dan pošlje proizvajalcu.
In the first study (n=18), the median cerebrospinal fluid concentration was 5.8 % (range 1 to 53.5 %) of the corresponding plasma concentration.
V prvi študiji (n=18) je mediana koncentracija v cerebrospinalni tekočini znašala 5,8 % (v intervalu od 1 do 53,5 %) odgovarjajoče koncentracije v plazmi.
In the first study 86% of the patients had a response to treatment.
V prvi študiji se je na zdravljenje odzvalo 86 % bolnikov.
In the first study in 49 patients with moderate to severe COPD, the rate of FEV1 reduction > 15% from baseline was 12% and 6% following Rapiscan and placebo dosing, respectively (p=0.31).
V prvi študiji pri 49 bolnikih z blago do resno KOPB je bila stopnja zmanjšanja FEV1 > 15% od izhodišča 12% po dajanju zdravila Rapiscan in 6% po placebu (p = 0,31).
In the first study in aHUS, platelet counts increased and were within normal levels in 82% of the patients, while 87% (13 out of 15 patients) with initially low platelet counts achieved platelet count normalisation and 76% achieved haematological normalisation.
V prvi študiji pri atipičnem hemolitično-uremičnem sindromu so se ravni trombocitov povečale in dosegle normalno raven pri 82 % bolnikov, medtem ko je pri 87 % (13 od 15) bolnikov z nizkimi začetnimi ravnmi trombocitov prišlo do normalizacije števila trombocitov, pri 76 % pa do hematološke normalizacije.
In the first study in HL, 75% of patients (76 out of 102) responded partially or completely to treatment.
V prvi študiji bolnikov s Hodgkinovim limfomom se je 75 % (76 od 102) bolnikov deloma ali popolnoma odzvalo na zdravljenje.
In the first study in patients with SEGA, the main brain tumour shrank by half in approximately 30% of patients and by about a third in around 70% of patients.
V prvi študiji pri bolnikih s subependimskim gigantoceličnim astrocitomom se je glavni možganski tumor zmanjšal za polovico pri okoli 30 % bolnikov in za eno tretjino pri okoli 70 % bolnikov.
In the first study in women weighing 60 kg or less, the number of eggs collected from each woman was 13.3 for those treated with Elonva and 10.6 for those treated with follitropin beta.
V prvi študiji, v kateri so sodelovale ženske s telesno maso pod 60 kg, so pri vsaki posameznici, ki se je zdravila z zdravilom Elonva, odvzeli 13,3 jajčeca, medtem ko so jih pri posameznicah, zdravljenih s folitropinom beta odvzeli 10,6.
In the first study involving over 2,400 men who have sex with men, 3.9% (48 out of 1,224) individuals taking Truvada tested positive for HIV-1 infection compared with 6.8% (83 out of 1,217) individuals taking placebo.
V prvi študiji, v katero je bilo vključenih 2 400 moških, ki spolno občujejo z moškimi, je bilo testiranje za okužbo z virusom HIV-1 pozitivno pri 3,9 % (48 od 1 224) tistih, ki so jemali zdravilo Truvada, v primerjavi s 6,8 % tistih, ki so jemali placebo.
In the first study looking at prevention of VTE and PE, blood clots or blood-clot related death occurred in 1.8% (26 out of 1430) of patients treated with Pradaxa, compared with 1.3% (18 out of 1426) of patients treated with warfarin.
V prvi študiji preprečevanja globoke venske tromboze in pljučne embolije, so se krvni strdki oziroma smrt bolnika zaradi krvnih strdkov pojavili pri 1,8% (26 od 1 430) bolnikov, zdravljenih z zdravilom Pradaxa, v primerjavi z 1,3 % (18 od 1 426) bolnikov, zdravljenih z varfarinom.
In the first study of newly diagnosed multiple myeloma, patients taking Revlimid (plus melphalan and prednisone) lived longer without their disease getting worse (27.4 months) than patients in the placebo group (14.3 month).
V prvi študiji pri bolnikih z novo odkritim mielomom so bolniki, ki so jemali Revlimid (skupaj z melfalanom in prednizonom) brez poslabšanja bolezni (27,4 meseca) živeli dlje kot bolniki v skupini, ki je jemala placebo (14,3 meseca).
In the first study of previously untreated patients, the average overall survival was 20.3 months in the patients adding Avastin and 15.6 months in those receiving chemotherapy alone.
V prvi študiji predhodno nezdravljenih bolnikov je bil povprečni skupni čas preživetja 20,3 meseca pri bolnikih, ki so prejemali tudi zdravilo Avastin, in 15,6 meseca pri tistih, ki so prejemali samo kemoterapijo.
In the first study, 19% of the patients adding Rapamune had failed treatment after six months (53 out of 284), compared with 32% of those adding azathioprine (52 out of 161).
V prvi študiji je bilo zdravljenje po šestih mesecih neuspešno pri 19 % bolnikov (53 od 284), ki so jim dodajali zdravilo Rapamune, in pri 32 % bolnikov (52 od 161), ki so jim dodajali azatioprin.
In the first study, 22% of the patients with relapsing MS who were treated with Avonex and 35% of the patients treated with placebo had a worsening of disability by the end of two years.
V prvi študiji se je pri 22 % bolnikov s ponavljajočo se multiplo sklerozo, zdravljenih z zdravilom Avonex, in pri 35 % bolnikov, zdravljenih s placebom, prizadetost poslabšala do konca drugega leta.
In the first study, 31% (55 out of 176) of patients receiving Signifor responded to treatment, compared with 19% (35 out of 182) of patients receiving octreotide.
V prvi študiji se je 31 % (55 od 176) bolnikov, ki so prejemali zdravilo Signifor, odzvalo na zdravljenje v primerjavi z 19 % (35 od 182) bolnikov, ki so prejemali oktreotid.
In the first study, 43% of the patients receiving Myocet or standard doxorubicin in combination with cyclophosphamide responded to treatment.
V prvi študiji se je na zdravljenje odzvalo 43 % bolnic, ki so prejemale zdravilo Myocet ali standardni doksorubicin v kombinaciji s ciklofosfamidom.
In the first study, 46% of the patients treated with Perjeta plus trastuzumab and docetaxel responded to treatment, compared with 29% of patients who received trastuzumab and docetaxel alone.
V prvi študiji se je na zdravljenje odzvalo 46 % bolnikov, ki so jih zdravili z zdravilom Perjeta ter trastuzumabom in docetakselom, v primerjavi z 29 % bolnikov, ki so prejemali samo trastuzumab in docetaksel.
In the first study, 600 patients with fluctuations were given Ongentys, entacapone (another medicine for Parkinson’s disease) or placebo (a dummy treatment), in addition to their current levodopa / DDCI combination.
V prvi študiji je 600 bolnikov z nihanji poleg kombinacije z levodopo/zaviralci DDK, ki so jo že prejemali, prejemalo zdravilo Ongentys, entakapon (drugo zdravilo proti Parkinsonovi bolezni) ali placebo (zdravilo brez zdravilne učinkovine).
In the first study, 61% of the patients adding the approved dose of Orencia to methotrexate had a reduction in symptoms (70 out of 115), compared with 35% of the patients adding placebo (42 out of 119) after 6 months.
V prvi študiji je pri 61 % (70 od 115) bolnikov, ki so odobrenemu odmerku zdravila Orencia dodajali metotreksat, po šestih mesecih prišlo do zmanjšanja simptomov v primerjavi s 35 % (42 od 119) bolnikov, ki so kot dodatek jemali placebo.
In the first study, 66% of women using Senshio reported relief from vaginal dryness (mild or no symptoms) after 12 weeks’ treatment compared with 49% in the placebo group.
V prvi študiji je 66 % žensk, ki so uporabljale zdravilo Senshio, po 12 tednih zdravljenja poročalo o zmanjšanju suhosti nožnice (blagi simptomi ali odsotnost simptomov) v primerjavi z 49 % v skupini, ki je prejemala placebo.
In the first study, 91.5% of women taking Esmya for three months had reduced menstrual bleeding compared with 18.8% of women taking placebo.
V prvi študiji se je menstrualna krvavitev zmanjšala pri 91,5 % žensk, ki so zdravilo Esmya jemale tri mesece.
In the first study, a long-term prospective cohort study, approximately 7,600 children vaccinated in 1995 with varicella vaccine in their second year of life were actively followed for 14 years in order to estimate the occurrence of varicella and herpes zoster.
V prvi, dolgoročni prospektivni kohortni študiji so leta 1995 približno 7.600 otrok cepili s cepivom proti noricam v drugem letu starosti in jih potem aktivno spremljali 14 let, da bi ugotovili pojav noric ali pasavca.
In the first study, adding Comtan increased the ‘on’ time by 1 hour and 18 minutes more than adding placebo.
V prvi študiji je dodajanje zdravila Comtan podaljšalo trajanje stanja „vklopa“ za 1 uro in 18 minut v primerjavi s placebom.
In the first study, adding Comtess increased the ‘on’ time by 1 hour and 18 minutes more than adding placebo.
V prvi študiji je dodajanje zdravila Comtess podaljšalo trajanje stanja „vklopa“ za 1 uro in 18 minut v primerjavi s placebom.
In the first study, after one year, patients receiving Lucentis could see about 6 letters more than those receiving sham injections.
V prvi študiji so bolniki, ki so prejemali zdravilo Lucentis, po enem letu lahko videli šest črk več kot tisti, ki so prejemali navidezne injekcije.
In the first study, among the 39 children and young adults whose cancer had not responded to two or more previous treatments, five (13%) had a complete response to treatment after a month, with no evidence of disease and normal blood counts.
V prvi študiji je od 39 otrok in mlajših odraslih oseb, ki se niso odzvali na najmanj dve predhodni zdravljenji raka, po enem mesecu doseglo popoln odziv na zdravljenje pet bolnikov (13 %), pri čemer niso imeli več znakov bolezni, njihova krvna slika pa je bila normalna.
In the first study, ANORO 55/22 micrograms demonstrated a statistically significant and clinically relevant improvement (based on a minimal clinically important difference (MCID) between 45 to 85 seconds) over placebo in exercise endurance time (EET) obtained 3 hours after dosing at Week 12 (69.4 seconds [p=0.003]).
V prvi študiji je zdravilo ANORO 55/22 mikrogramov v primerjavi s placebom po 12 tednih statistično značilno in klinično pomembno izboljšalo (na podlagi minimalne klinično pomembne razlike [MCID – minimal clinically important difference] med 45 in 85 sekund) čas obremenitvene vzdržljivosti (EET – exercise endurance time), dosežen 3 ure po uporabi (69,4 sekunde [p = 0,003]).
In the first study, around 23% of the patients receiving Ozurdex had an increase in BCVA of at least 15 letters after 180 days compared with 17% of the patients receiving the sham treatment.
V prvi študiji se je pri približno 23 % bolnikov, ki so prejeli zdravilo Ozurdex, najboljša korigirana ostrina vida (BCVA) po 180 dneh izboljšala za 15 črk v primerjavi s 17 % bolnikov, ki so prejeli navidezno zdravljenje.
In the first study, around 51% of patients receiving induction treatment with Simponi (starting at 200 mg) responded to treatment after 6 weeks, compared with around 30% of patients given placebo.
V prvi študiji se je po šestih tednih na zdravljenje odzvalo približno 51 % bolnikov, ki so prejemali uvodno zdravljenje z zdravilom Simponi (z uvodnim odmerkom 200 mg), v primerjavi z okrog 30 % bolnikov, ki so prejemali placebo.
In the first study, in 43% of patients Benlysta 10 mg/kg was effective, compared with 34% of patients who were given placebo.
V prvi študiji je bilo zdravilo Benlysta učinkovito pri 43 % bolnikov, ki so prejemali odmerek 10 mg/kg, v primerjavi s 34 % bolnikov, ki so prejemali placebo.
In the first study, in lung cancer patients with EGFR activating mutations, patients taking Tarceva as initial treatment survived without their disease getting worse for an average of 9.7 months compared with 5.2 months for those receiving other chemotherapy medicines.
V prvi študiji, ki je vključevala bolnike s pljučnim rakom z EGFR-aktivirajočimi mutacijami, je bil pri bolnikih, ki so jemali zdravilo Tarceva kot začetno zdravljenje, čas do poslabšanja bolezni v povprečju 9,7 meseca, pri bolnikih, ki so prejemali druge kemoterapevtike, pa 5,2 meseca.
In the first study, in which patients were also given methotrexate, after 14 weeks, 55% patients who received Simponi (49 out of 89) achieved 20% reductions compared with 33% (44 out of 133) of patients who received placebo.
V prvi študiji revmatoidnega artritisa, v kateri so bolniki prejeli tudi metotreksat, je po 14 tednih prišlo do 20-odstotnega zmanjšanja simptomov pri 55 % (49 od 89) bolnikov, ki so prejemali zdravilo Simponi, v primerjavi s 33 % (44 od 133) bolnikov, ki so prejemali placebo.
In the first study, involving 391 patients whose disease did not respond to or had come back after previous treatment, Imbruvica was more effective than ofatumumab (another cancer medicine) at delaying progression of the cancer.
V glavni študiji s 391 bolniki, pri katerih se bolezen ni odzvala na predhodno zdravljenje ali se je po njem ponovila, se je zdravilo Imbruvica izkazalo za učinkovitejše od ofatumumaba (drugega zdravila za zdravljenje raka) pri upočasnitvi napredovanja raka.
In the first study, involving 715 patients, Stribild was compared with the combination of ritonavir, atazanavir plus a medicine containing emtricitabine and tenofovir disoproxil (which are also contained in Stribild).
V prvi študiji, v katero je bilo vključenih 715 bolnikov, so zdravilo Stribild primerjali s kombinacijo ritonavirja, atazanavirja in zdravila z emtricitabinom in dizoproksiltenofoviratom (ki sta prav tako prisotna v zdravilu Stribild).
In the first study, Kiovig was as effective as the standard treatment in preventing infections and reducing antibiotic use.
V prvi študiji je bilo zdravilo Kiovig pri preprečevanju okužb in zmanjševanju uporabe antibiotikov enako učinkovito kot standardno zdravljenje.
In the first study, Kiovig was used to replace antibodies in 22 patients with PID who had very low or no levels of immunoglobulin.
V prvi študiji se je zdravilo Kiovig uporabilo za nadomestitev protiteles pri 22 bolnikih s sindromom primarne imunske pomanjkljivosti, ki so imeli zelo nizko koncentracijo imunoglobulina oziroma ga sploh niso imeli.
In the first study, M-M-RVAXPRO triggered the same level of immune response as the comparator.
V prvi študiji je cepivo M-M-RVAXPRO sprožilo enako stopnjo imunskega odziva kot primerjalno cepivo.
In the first study, Myocet was compared with standard (non-liposomal) doxorubicin, both in combination with cyclophosphamide, in 297 women.
V prvi študiji so zdravilo Myocet primerjali s standardnim (neliposomskim) doksorubicinom, obe zdravili pa so dajali v kombinaciji s ciklofosfamidom pri 297 ženskah.
In the first study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 16.3% (21 out of 129) for Mirvaso compared with 3.1% (4 out of 131) for placebo.
V prvi študiji je na 1. dan odstotek bolnikov, pri katerih se je 3 ure po nanosu rdečina obraza zmanjšala, znašal 16,3 % (21 od 129) za zdravilo Mirvaso in 3,1 % (4 od 131) za placebo.
In the first study, over 50% of patients receiving Cinryze had started having improvements two hours into treatment, compared with 33% of patients given placebo.
V prvi študiji se je pri več kot 50 % bolnikov, ki so prejemali zdravilo Cinryze, pokazalo izboljšanje v dveh urah po začetku zdravljenja v primerjavi s 33 % bolnikov, ki so prejemali placebo.
In the first study, patients survived for around 10 months on treatment with Yervoy or the combination treatment, compared with 6 months on gp100 alone.
V prvi študiji so bolniki, ki so se zdravili z zdravilom Yervoy ali kombinacijo zdravil, preživeli približno 10 mesecev, bolniki, ki so se zdravili samo z zdravilom gp100, pa 6 mesecev.
In the first study, patients taking Stayveer had an average of 1.4 new digital ulcers after 16 weeks, compared with 2.7 in the patients taking placebo.
V prvi študiji so pri bolnikih, ki so jemali zdravilo Stayveer, po 16 tednih v povprečju zabeležili 1,4 nove razjede prstov, pri bolnikih, ki so jemali placebo, pa 2,7.
In the first study, patients treated with Zytiga lived for just under 15 months from the start of treatment, while patients given placebo lived for just under 11 months.
V prvi študiji so bolniki, ki so bili zdravljeni z zdravilom Zytiga, živeli nekaj manj kot 15 mesecev od začetka zdravljenja, medtem ko so bolniki, ki so prejemali placebo, živeli nekaj manj kot 11 mesecev.
In the first study, patients who were given Invega had a fall in their symptom score of between 27.4 and 30.6 compared with 21.7 in patients who were given placebo.
V prvi študiji se je pri bolnikih, ki so jemali zdravilo Invega, rezultat vrednotenja simptomov znižal za 27,4 do 30,6 točke, medtem ko se je pri bolnikih, ki so jemali placebo, znižal za 21,7 točke.
In the first study, previously untreated patients with wild-type RAS receiving Vectibix in combination with FOLFOX lived for an average of 10.1 months without the disease getting worse compared with 7.9 months for patients receiving FOLFOX alone.
V prvi študiji so predhodno nezdravljeni bolniki z divjim tipom gena RAS prejemali zdravilo Vectibix v kombinaciji s kemoterapijo FOLFOX, pri čemer je bil čas preživetja teh bolnikov brez poslabšanja bolezni 10,1 meseca, v primerjavi s 7,9 meseca pri bolnikih, ki so bili zdravljeni le s kemoterapijo FOLFOX.
In the first study, Privigen was used as replacement therapy in 80 patients with PID, with the medicine being infused every three or four weeks.
V prvi je bilo zdravilo Privigen uporabljeno kot nadomestno zdravljenje pri 80 bolnikih s sindromom primarne imunske pomanjkljivosti, pri čemer se je zdravilo infundiralo vsake tri ali štiri tedne.
In the first study, Quinsair was shown to be better than placebo at improving the patients’ forced expiratory volume in one second (FEV1), adjusted for the patient’s age, height and sex.
Prva študija je pokazala, da je bilo zdravilo Quinsair boljše od placeba pri izboljšanju forsiranega ekspiracijskega volumna bolnikov v eni sekundi (FEV1), pri čemer so rezultate prilagodili glede na bolnikovo starost, višino in spol.
In the first study, RoActemra was more effective than placebo in treating rheumatoid arthritis: after 6 months of treatment with RoActemra, 61% of patients responded to treatment compared with 32% on placebo.
V prvi študiji je bilo zdravilo RoActemra učinkovitejše od placeba pri zdravljenju revmatoidnega artritisa: po šestmesečnem zdravljenju se je nanj odzvalo 61 % v primerjavi s 32 % bolnikov, ki so prejemali placebo.
In the first study, the main measure of effectiveness was the number of patients whose platelet count had increased to at least 50,000 cells per microlitre after six weeks.
V prvi študiji je bilo glavno merilo učinkovitosti število bolnikov, pri katerih se je število trombocitov po šestih tednih povečalo na najmanj 50 000 celic na mikroliter.
In the first study, the patients had an average of 0.08 serious infections per year.
V prvi študiji so imeli bolniki v povprečju 0,08 resne okužbe na leto.
In the first study, the percentage of patients who experienced a decrease in seizure frequency of at least 50% was 37.6% for patients taking 8 mg Fycompa and 36.1% for patients taking 12 mg Fycompa, compared with 26.4% of patients taking placebo.
V prvi študiji je delež bolnikov, pri katerih je prišlo do najmanj 50-odstotnega upada pogostosti napadov, znašal 37,6 % pri bolnikih, ki so jemali
In the first three placebo studies, it took an average of 116 days for fibrillation to come back in the patients taking Multaq compared with 53 days in the patients taking placebo.
V prvih treh študijah s placebom se je fibrilacija pri bolnikih, ki so jemali zdravilo Multaq, ponovila v povprečju čez 116 dni, v primerjavi s 53 dnevi pri bolnikih, ki so jemali placebo.
In the first trial, over 650 patients with stage IIb-c, III or IV primary ovarian cancer received a maximum of 9 treatment courses of paclitaxel (175 mg/m2 over 3 hours) followed by cisplatin (75 mg/m2) or control.
V prvem preskušanju je več kot 650 bolnic s primarnim rakom jajčnikov faze IIb-c, III ali IV prejelo največ 9 krogov zdravljenja s paklitakselom (175 mg/m2 v 3 urah) in nato cisplatin (75 mg/m2) ali kontrolo.
In the first two studies, a total of 614 patients were given either Invega or placebo.
V prvih dveh študijah je skupno 614 bolnikov prejemalo bodisi zdravilo Invega bodisi placebo.
In the first two studies, among patients who had recently started having atrial fibrillation, heart rhythm returned to normal in 51% of those receiving Brinavess (118 out of 231) compared with 4% (6 out of 159) of those taking placebo.
V prvih dveh študijah se je pri bolnikih z nedavnim pojavom atrijske fibrilacije srčni utrip normaliziral pri 51 % prejemnikov zdravila Brinavess (118 od 231) in pri 4 % prejemnikov placeba (6 od 159).
In the first two studies, Faslodex was as effective as anastrozole: the women receiving Faslodex lived for an average of 5.4 months without their disease getting worse, compared with 4.1 months in those taking anastrozole.
V prvih dveh študijah je bilo zdravilo Faslodex enako učinkovito kot anastrozol: bolnice, ki so prejemale zdravilo Faslodex, so v povprečju živele 5,4 meseca brez poslabšanja bolezni v primerjavi s 4,1 meseca pri tistih, ki so jemale anastrozol.
In the first two studies, most of the 722 patients were also taking ciclosporin and corticosteroids (‘dual therapy’), with some patients also taking azathioprine or mycophenolate mofetil.
V prvih dveh študijah je večina od 722 bolnikov jemala tudi ciklosporin in kortikosteroide (dvotirno zdravljenje), nekateri bolniki pa so jemali tudi azatioprin ali mofetilmikofenolat.
In the first two studies, the number of relapses per year among patients treated with Gilenya was around half the number seen in patients given placebo.
V prvih dveh študijah je bilo število recidivov v enem letu pri bolnikih, zdravljenih z zdravilom Gilenya, okoli polovico manjše v primerjavi s številom recidivov pri bolnikih, ki so prejemali placebo.
In the five surgeries that occurred during the study, Nuwiq was rated as excellent in preventing bleeding episodes for four surgeries and as moderate to prevent bleeding during one surgical intervention.
Pri petih kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Nuwiq pri štirih ocenjeno kot odlično pri preprečevanju krvavitev, pri enem kirurškem posegu pa kot zmerno učinkovito pri preprečevanju krvavitev.
In the fixed weekly interval arm, subjects received ALPROLIX for routine prophylaxis starting at 50 IU/kg.
V kraku s fiksnim tedenskim intervalom so osebe prejemale zdravilo ALPROLIX za redno profilakso z začetnim odmerkom 50 i.e./kg.
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs.
V podskupini, ki je prejemala zdravljenje po shemi FOLFOX, je bila mediana preživetja brez napredovanja bolezni 8,6 meseca pri bolnikih, ki so prejemali placebo, ter 9,4 meseca pri bolnikih, ki so se zdravili z bevacizumabom; razmerje ogroženosti = 0,89, 97,5-% interval zaupanja = [0,73; 1,08]; p-vrednost = 0,1871.
In the following 16 weeks, all patients received Ilaris every eight weeks.
V naslednjih 16 tednih so vsi bolniki vsakih osem tednov prejeli zdravilo Ilaris.
In the following cases, Quintanrix should not be given to your child.
V naslednjih primerih se cepivo Quintanrix vašemu otroku ne sme dati.
In the following cases, your doctor can determine the right time and scheme of vaccination for your child.
V naslednjih primerih lahko vaš zdravnik določi ustrezen čas in shemo cepljenja za vašega otroka.
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests) :
V sledečih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva posebno skrb (npr. prilagoditev odmerka insulina, preiskave krvi in urina):